Gilead licenses three dual-masked T-cell engagers from Vir in a deal worth up to about $1.9B
- Vir will discover, design and optimize three T-cell engagers against solid-tumor antigens on its dual-masked PRO-XTEN platform; Gilead holds exclusive rights to nominate candidates and then develops and commercializes them.
- Vir receives $90M up front ($65M cash plus a $25M equity investment) and $45M in near-term preclinical milestones.
- Up to $1.74B in development, regulatory and commercial milestones and tiered royalties could follow.
💡 Points
This is Gilead's third T-cell engager move in a short stretch (Merus, Ouro, now Vir), so the oncology thesis is clearly masked, conditional-activation TCEs for solid tumors. For Vir, it's the second platform deal this year and non-dilutive cash that lets it fund its own pipeline; the equity premium shows Gilead's commitment. Preclinical risk stays high.
Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs ↗